Kura Oncology, Inc.
KURANASDAQHealthcare● Active
$8.65
$-0.09(-1.09%)
Market Cap$767454426
P/E Ratio—
52W High$12.49
52W Low$5.45
Kura Oncology, Inc. (KURA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KURA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $67.48M | $53.88M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.06M | $0.00M | $0.85M | $0.00M | $0.00M |
| Gross Profit | $67.42M | $53.88M | ($0.85M) | $0.00M | $0.00M |
| Gross Margin %(computed) | 99.92% | 100.00% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $251.07M | $169.97M | $115.23M | $92.81M | $84.72M |
| G&A Expenses | $119.98M | $77.11M | $50.57M | $47.05M | $46.54M |
| Total Operating Expenses | $371.06M | $247.08M | $164.96M | $139.87M | $131.26M |
| Operating Income | ($303.63M) | ($193.19M) | ($165.80M) | ($139.87M) | ($131.26M) |
| Operating Margin %(computed) | -449.94% | -358.55% | — | — | — |
| Interest Income | $26.77M | $22.85M | $14.72M | $4.25M | $1.21M |
| Interest Expense | $1.51M | $1.62M | $1.55M | $0.23M | $0.41M |
| Income Before Tax | ($278.37M) | ($171.97M) | ($152.63M) | ($135.84M) | ($130.47M) |
| Income Tax Expense | $0.30M | $2.02M | $0.00M | $0.00M | $0.00M |
| Net Income | ($278.67M) | ($173.98M) | ($152.63M) | ($135.84M) | ($130.47M) |
| Net Margin %(computed) | -412.95% | -322.89% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.18 | $-2.02 | $-2.08 | $-2.03 | $-1.97 |
| Wtd Avg Shares | 87.68M | 86.16M | 73.23M | 66.99M | 66.35M |
| EBITDA | ($275.82M) | ($169.50M) | ($150.23M) | ($134.85M) | ($129.49M) |
| EBITDA Margin %(computed) | -408.74% | -314.57% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Kura Oncology, Inc. data
About Kura Oncology, Inc. (KURA) Income Statement
Kura Oncology, Inc. (KURA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, KURA reported revenue of $0.07B, gross profit of $0.07B (gross margin 99.92%), and net income of ($0.28B) — a net profit margin of -412.95%.
Frequently asked questions
KURA · 4 questionsKura Oncology, Inc. (KURA) reported revenue of $0.07B for 2025, up 25.2% year-over-year.
KURA revenueKURA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08